Genix Pharmaceuticals Corporation (TSXV:GENX)
Canada
· Delayed Price · Currency is CAD 0.0200
0.00 (0.00%)
At close: Mar 5, 2026
Genix Pharmaceuticals Income Statement
Financials in millions CAD. Fiscal year is November - October.
Millions CAD. Fiscal year is Nov - Oct.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 | 2020 - 2016 |
| Revenue | - | 0 | 0.01 | - | - | Upgrade
|
| Revenue Growth (YoY) | - | -67.19% | - | - | - | Upgrade
|
| Cost of Revenue | - | 0.18 | 0.01 | - | 0 | Upgrade
|
| Gross Profit | - | -0.18 | 0 | - | -0 | Upgrade
|
| Selling, General & Admin | 0.12 | 0.15 | 0.23 | 0.18 | 0.26 | Upgrade
|
| Amortization of Goodwill & Intangibles | 0 | 0 | 0.54 | 0.54 | 0.52 | Upgrade
|
| Operating Expenses | 0.13 | 0.18 | 0.84 | 1 | 1.61 | Upgrade
|
| Operating Income | -0.13 | -0.36 | -0.83 | -1 | -1.61 | Upgrade
|
| Interest Expense | -0.17 | -0.12 | -0.05 | -0.01 | -0 | Upgrade
|
| Interest & Investment Income | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Currency Exchange Gain (Loss) | -0 | -0 | -0.01 | -0.03 | 0 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.03 | -0.06 | -0.05 | -0.03 | -0.05 | Upgrade
|
| EBT Excluding Unusual Items | -0.33 | -0.55 | -0.94 | -1.07 | -1.65 | Upgrade
|
| Asset Writedown | -0.01 | - | -3.46 | - | - | Upgrade
|
| Other Unusual Items | - | 0.47 | - | - | - | Upgrade
|
| Pretax Income | -0.34 | -0.07 | -4.4 | -1.07 | -1.65 | Upgrade
|
| Earnings From Continuing Operations | -0.34 | -0.07 | -4.4 | -1.07 | -1.65 | Upgrade
|
| Net Income | -0.34 | -0.07 | -4.4 | -1.07 | -1.65 | Upgrade
|
| Net Income to Common | -0.34 | -0.07 | -4.4 | -1.07 | -1.65 | Upgrade
|
| Shares Outstanding (Basic) | 60 | 59 | 59 | 59 | 59 | Upgrade
|
| Shares Outstanding (Diluted) | 60 | 59 | 59 | 59 | 59 | Upgrade
|
| Shares Change (YoY) | 0.54% | - | - | - | 18.55% | Upgrade
|
| EPS (Basic) | -0.01 | -0.00 | -0.07 | -0.02 | -0.03 | Upgrade
|
| EPS (Diluted) | -0.01 | -0.00 | -0.07 | -0.02 | -0.03 | Upgrade
|
| Free Cash Flow | -0.12 | -0.19 | -0.22 | -0.22 | -0.43 | Upgrade
|
| Free Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.01 | Upgrade
|
| Gross Margin | - | - | 26.43% | - | - | Upgrade
|
| Operating Margin | - | -8986.67% | -6737.05% | - | - | Upgrade
|
| Profit Margin | - | -1806.86% | -35600.34% | - | - | Upgrade
|
| Free Cash Flow Margin | - | -4624.54% | -1787.27% | - | - | Upgrade
|
| EBITDA | -0.12 | -0.36 | -0.29 | -0.46 | -1.09 | Upgrade
|
| D&A For EBITDA | 0 | 0 | 0.55 | 0.54 | 0.52 | Upgrade
|
| EBIT | -0.13 | -0.36 | -0.83 | -1 | -1.61 | Upgrade
|
| Revenue as Reported | - | 0 | 0.01 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.